All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Guidance for management strategies in early myelofibrosis
Bookmark this article
|
A summary of best practice recommendations for the management of patients with early myelofibrosis (MF) has been published in Current Hematologic Malignancy Reports by Bose.1 Guidance for early diagnosis, risk satification, and symptom management were summarized.1 |
| Key learnings1 |
|
Risk stratification tools, including the Dynamic International Prognostic Scoring System (DIPSS) and Mutation-Enhanced International Prognostic Scoring System (MIPSS)70 are recommended to determine accurate risk status in early MF. |
|
Molecular testing for mutations and adverse prognostic markers is recommended during the initial workup to help tailor the treatment plan to the patient’s specific genetic profile. |
|
Early initiation of treatment is crucial in both patients with intermediate-2 risk or higher, as well as patients who are symptomatic with lower risk. |
|
Data support the early use of ruxolitinib in higher-risk patients, to improve overall survival and symptom burden. |
|
Active treatment for significant symptoms, such as fatigue and splenomegaly, is recommended regardless of risk status. |
| These findings highlight the importance of active treatment in managing early MF to improve survival and reduce symptom burden and disease progression. |
- Bose P. Management of Patients with Early Myelofibrosis: A Discussion of Best Practices. Curr Hematol Malig Rep. 2024;19(3):111-119. DOI: 1007/s11899-024-00729-8.
Publication summaries
50%
Visual abstracts
25%
Expert videos
15%
Expert podcasts
10%
20 votes
More about...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox